186 related articles for article (PubMed ID: 17219149)
1. Monoclonal antibody 2C5-modified doxorubicin-loaded liposomes with significantly enhanced therapeutic activity against intracranial human brain U-87 MG tumor xenografts in nude mice.
Gupta B; Torchilin VP
Cancer Immunol Immunother; 2007 Aug; 56(8):1215-23. PubMed ID: 17219149
[TBL] [Abstract][Full Text] [Related]
2. Tumor-targeted nanomedicines: enhanced antitumor efficacy in vivo of doxorubicin-loaded, long-circulating liposomes modified with cancer-specific monoclonal antibody.
ElBayoumi TA; Torchilin VP
Clin Cancer Res; 2009 Mar; 15(6):1973-80. PubMed ID: 19276264
[TBL] [Abstract][Full Text] [Related]
3. Enhanced cytotoxicity of monoclonal anticancer antibody 2C5-modified doxorubicin-loaded PEGylated liposomes against various tumor cell lines.
Elbayoumi TA; Torchilin VP
Eur J Pharm Sci; 2007 Nov; 32(3):159-68. PubMed ID: 17707615
[TBL] [Abstract][Full Text] [Related]
4. Tumor-specific anti-nucleosome antibody improves therapeutic efficacy of doxorubicin-loaded long-circulating liposomes against primary and metastatic tumor in mice.
Elbayoumi TA; Torchilin VP
Mol Pharm; 2009; 6(1):246-54. PubMed ID: 19049322
[TBL] [Abstract][Full Text] [Related]
5. Doxorubicin in TAT peptide-modified multifunctional immunoliposomes demonstrates increased activity against both drug-sensitive and drug-resistant ovarian cancer models.
Apte A; Koren E; Koshkaryev A; Torchilin VP
Cancer Biol Ther; 2014 Jan; 15(1):69-80. PubMed ID: 24145298
[TBL] [Abstract][Full Text] [Related]
6. Tumor-targeted liposomes: doxorubicin-loaded long-circulating liposomes modified with anti-cancer antibody.
Lukyanov AN; Elbayoumi TA; Chakilam AR; Torchilin VP
J Control Release; 2004 Nov; 100(1):135-44. PubMed ID: 15491817
[TBL] [Abstract][Full Text] [Related]
7. Antinucleosome antibody-modified liposomes and lipid-core micelles for tumor-targeted delivery of therapeutic and diagnostic agents.
Elbayoumi TA; Pabba S; Roby A; Torchilin VP
J Liposome Res; 2007; 17(1):1-14. PubMed ID: 17454399
[TBL] [Abstract][Full Text] [Related]
8. Enhanced accumulation of long-circulating liposomes modified with the nucleosome-specific monoclonal antibody 2C5 in various tumours in mice: gamma-imaging studies.
Elbayoumi TA; Torchilin VP
Eur J Nucl Med Mol Imaging; 2006 Oct; 33(10):1196-205. PubMed ID: 16763815
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of interleukin-13 receptor-targeted liposomal doxorubicin in the intracranial brain tumor model.
Madhankumar AB; Slagle-Webb B; Wang X; Yang QX; Antonetti DA; Miller PA; Sheehan JM; Connor JR
Mol Cancer Ther; 2009 Mar; 8(3):648-54. PubMed ID: 19276162
[TBL] [Abstract][Full Text] [Related]
10. Targeted Delivery of Combination Therapeutics Using Monoclonal Antibody 2C5-Modified Immunoliposomes for Cancer Therapy.
Narayanaswamy R; Torchilin VP
Pharm Res; 2021 Mar; 38(3):429-450. PubMed ID: 33655395
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal antibody 2C5-mediated binding of liposomes to brain tumor cells in vitro and in subcutaneous tumor model in vivo.
Gupta B; Levchenko TS; Mongayt DA; Torchilin VP
J Drug Target; 2005 Jul; 13(6):337-43. PubMed ID: 16278153
[TBL] [Abstract][Full Text] [Related]
12. Enhanced doxorubicin delivery to hepatocellular carcinoma cells via CD147 antibody-conjugated immunoliposomes.
Wang J; Wu Z; Pan G; Ni J; Xie F; Jiang B; Wei L; Gao J; Zhou W
Nanomedicine; 2018 Aug; 14(6):1949-1961. PubMed ID: 29045824
[TBL] [Abstract][Full Text] [Related]
13. Chloride channel-mediated brain glioma targeting of chlorotoxin-modified doxorubicine-loaded liposomes.
Xiang Y; Liang L; Wang X; Wang J; Zhang X; Zhang Q
J Control Release; 2011 Jun; 152(3):402-10. PubMed ID: 21435361
[TBL] [Abstract][Full Text] [Related]
14. Novel drug delivery liposomes targeted with a fully human anti-VEGF165 monoclonal antibody show superior antitumor efficacy in vivo.
Shi C; Cao H; He W; Gao F; Liu Y; Yin L
Biomed Pharmacother; 2015 Jul; 73():48-57. PubMed ID: 26211582
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo.
Mamot C; Drummond DC; Noble CO; Kallab V; Guo Z; Hong K; Kirpotin DB; Park JW
Cancer Res; 2005 Dec; 65(24):11631-8. PubMed ID: 16357174
[TBL] [Abstract][Full Text] [Related]
16. Multifunctional PEGylated 2C5-immunoliposomes containing pH-sensitive bonds and TAT peptide for enhanced tumor cell internalization and cytotoxicity.
Koren E; Apte A; Jani A; Torchilin VP
J Control Release; 2012 Jun; 160(2):264-73. PubMed ID: 22182771
[TBL] [Abstract][Full Text] [Related]
17. Tumor-specific antibody-mediated targeted delivery of Doxil reduces the manifestation of auricular erythema side effect in mice.
Elbayoumi TA; Torchilin VP
Int J Pharm; 2008 Jun; 357(1-2):272-9. PubMed ID: 18329201
[TBL] [Abstract][Full Text] [Related]
18. Targeting CD44 expressing cancer cells with anti-CD44 monoclonal antibody improves cellular uptake and antitumor efficacy of liposomal doxorubicin.
Arabi L; Badiee A; Mosaffa F; Jaafari MR
J Control Release; 2015 Dec; 220(Pt A):275-286. PubMed ID: 26518722
[TBL] [Abstract][Full Text] [Related]
19. Prostate cancer-specific monoclonal antibody 5D4 significantly enhances the cytotoxicity of doxorubicin-loaded liposomes against target cells in vitro.
Sawant RM; Cohen MB; Torchilin VP; Rokhlin OW
J Drug Target; 2008 Aug; 16(7):601-4. PubMed ID: 18686131
[TBL] [Abstract][Full Text] [Related]
20. Development of a fully human anti-PDGFRbeta antibody that suppresses growth of human tumor xenografts and enhances antitumor activity of an anti-VEGFR2 antibody.
Shen J; Vil MD; Prewett M; Damoci C; Zhang H; Li H; Jimenez X; Deevi DS; Iacolina M; Kayas A; Bassi R; Persaud K; Rohoza-Asandi A; Balderes P; Loizos N; Ludwig DL; Tonra J; Witte L; Zhu Z
Neoplasia; 2009 Jun; 11(6):594-604. PubMed ID: 19484148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
